C4 Therapeutics, Inc.

CCCC · Healthcare

$3.87

Capitalización: 476.11M USDRendimiento por dividendo: —
Advance¿Es buen momento para comprar C4 Therapeutics, Inc.? Pregunta a Copenvest AIObtén una lectura Advance con IA sobre timing, riesgo y qué hacen los inversores rastreados.Preguntar a Copenvest AI

Cargando gráfico…

Noticias

Últimos titulares de esta acción

GlobeNewswire4 sept 2026, 12:30

Nearly 7 in 10 Canadian employees surveyed expect trade with China to increase over the next two years, reveals CCCC 2026 survey

GlobeNewswire3 sept 2026, 11:00

C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting